Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026

Same author

Spatially resolved T cell receptor tracking reveals γδT cell localization to tumor-rich regions in high-risk neuroblastoma: A Report from the Children's Oncology Group.

medRxiv : the preprint server for health sciences·2026

Same author

Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma.

Translational oncology·2026

Same author

A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study.

JCO precision oncology·2026

Same author

Clinical and Biological Features of Response in Resistant Neuroblastoma to <sup>131</sup>I-Metaiodobenzylguanidine Radiotherapy in the Anti-GD2 Immunotherapy Era.

Pediatric blood & cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Ototoxicity in children treated for osteosarcoma.

Matthew J Lewis¹, Steven G DuBois, Brian Fligor

¹Department of Pediatric Hematology/Oncology, Dana Farber-Cancer Institute/Children's Hospital, Boston, Massachusetts 02115, USA.

Pediatric Blood & Cancer

|December 9, 2008

Summary

A modified cisplatin dosage (60 mg/m(2)/day for 2 days) significantly reduced hearing loss in pediatric osteosarcoma patients. This lower dose regimen is recommended over the higher single-day dose to mitigate ototoxicity risks.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Experiment Videos

Last Updated: Jun 27, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Area of Science:

Pediatric Oncology
Ototoxicity Research
Chemotherapy Side Effects

Background:

Cisplatin is a vital chemotherapy for osteosarcoma.
Ototoxicity risks associated with cisplatin in pediatric osteosarcoma are not well-defined.
This study aimed to identify hearing loss incidence and risk factors in children undergoing osteosarcoma treatment.

Purpose of the Study:

To determine the incidence of hearing loss in children treated for osteosarcoma.
To identify risk factors associated with cisplatin-induced ototoxicity.
To compare hearing loss rates between different cisplatin dosing regimens.

Main Methods:

Retrospective analysis of pediatric osteosarcoma patients (ages 3-18) treated between 1995-2004.
Audiograms were performed before, during, and after chemotherapy.
Fisher's exact test and logistic regression analyzed hearing loss predictors.

Main Results:

78% of patients receiving high-dose cisplatin (120 mg/m(2)/day) experienced hearing loss versus 30% with the modified dose (60 mg/m(2)/day for 2 days).
Independent predictors of hearing loss included age, cumulative cisplatin dose, and the high-dose regimen.
The modified 2-day regimen showed a 30% overall hearing loss rate and only 4% educationally significant hearing loss.

Conclusions:

Administering cisplatin at 60 mg/m(2)/day for 2 days resulted in a low incidence of significant hearing loss.
The high-dose cisplatin regimen (120 mg/m(2)/day) should be avoided due to its high ototoxicity rate.
This modified dosing strategy can help preserve hearing in pediatric osteosarcoma patients.